

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

C-33 A

RRID:CVCL_1094

Type: Cell Line

Proper Citation

RRID:CVCL_1094

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1094

Proper Citation: RRID:CVCL_1094

Description: Cell line C-33 A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-independent cervical squamous cell carcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1648218](#), [PMID:2990217](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7459858](#), [PMID:14114965](#), [PMID:15531914](#), [PMID:20215515](#), [PMID:24134916](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28261610](#), [PMID:29156801](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35692560](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: C-33 A

Synonyms: C33A, C33a, C33-A, C-33-A, C-33A, C33

Cross References: BTO:BTO_0001968, CLO:CLO_0002115, EFO:EFO_0002120, CLDB:cl7126, AddexBio:C0008003/382, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRM-HTB-31, ATCC:HTB-31, BCRC:60554, BCRJ:0348, BioSample:SAMN03473073, cancercellines:CVCL_1094, CCRID:1101HUM-PUMC000172, CCRID:1102HUM-

NIFDC00091, CCRID:3101HUMTCHu176, CCRID:4201HUM-CCTCC00144, CCTCC:GDC0144, Cell_Model_Passport:SIDM00889, ChEMBL-Cells:ChEMBL3308230, ChEMBL-Targets:ChEMBL2366313, ChEMBL-Targets:ChEMBL614370, CLS:305072, Cosmic:687505, Cosmic:760217, Cosmic:809226, Cosmic:846180, Cosmic:877470, Cosmic:925355, Cosmic:928905, Cosmic:1071910, Cosmic:1131520, Cosmic:1176610, Cosmic:1193030, Cosmic:1201776, Cosmic:1324210, Cosmic:1995353, Cosmic:2301537, Cosmic:2602729, Cosmic:2660188, Cosmic:2791020, Cosmic:2816218, Cosmic-CLP:687505, DepMap:ACH-001333, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687505, GEO:GSM253296, GEO:GSM675730, GEO:GSM685441, GEO:GSM1669637, IARC_TP53:324, ICLC:HTL02004, IGRhCellID:C33A, LINCS_LDP:LCL-1300, PharmacDB:C33A_150_2019, PRIDE:PXD030304, Progenetix:CVCL_1094, PubChem_Cell_line:CVCL_1094, Wikidata:Q54799738

ID: CVCL_1094

Record Creation Time: 20220427T215421+0000

Record Last Update: 20260920T001650+0000

Ratings and Alerts

No rating or validation information has been found for C-33 A.

No alerts have been found for C-33 A.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 791 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chhokar A, et al. (2026) Development of a novel multi-locus Flow-FISH based assay for detection of progressive cervical precancer lesions. BMC cancer, 26(1).

Xu R, et al. (2026) Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF- κ B/GSDMD Signaling Axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(6), e71636.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells, 15(1).

Zhang Y, et al. (2026) Dual-specificity phosphatase 14 inhibits the growth of cervical cancer cells by regulating the transforming growth factor-beta-activated kinase 1 and NOD-like receptor pyrin domain containing 3 inflammatory pathways. The Journal of international medical research, 54(4), 3000605261441200.

Su Q, et al. (2026) Galectin-1-Targeted Type-I/II Photosensitizers Activate the NF- κ B Pathway to Enhance Immunity and Treat High-Risk HPV-Associated Cervical Lesions. *ACS applied materials & interfaces*, 18(2), 3599.

Lou H, et al. (2026) PIK3CA mutant cervical cancer is selectively suppressed by PI3K γ inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy. *Neoplasia (New York, N.Y.)*, 76, 101305.

Yang D, et al. (2026) RNF125 promotes CD8 T cell-mediated anticancer immunity and suppresses the malignant phenotype of cervical cancer. *Molecular and cellular biochemistry*, 481(5), 2005.

Talpe-Nunes V, et al. (2026) GATA3 Inhibits the Expression of Viral E6/E7 Genes, and Its Expression Is Compromised During HPV-Mediated Cervical Carcinogenesis. *Journal of medical virology*, 98(7), e71034.

Li L, et al. (2026) Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage. *Cancer cell*.

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.

Wendel SO, et al. (2026) Targeting Cancer-Associated PCNA with AOH1996 Induces Mitotic Catastrophe and Enhances Cisplatin Therapy in Cervical Cancer. *Cancer research communications*, 6(5), 1220.

Lou H, et al. (2026) A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy. *medRxiv : the preprint server for health sciences*.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e11349.

Zhen Q, et al. (2025) Erucic Acid, Derived by *Lactobacillus Crispatus*, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR- γ Signaling Pathway. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(48), e12599.

Ashraf N, et al. (2025) Factors that determine cell fate in mitotically arrested cancer cells. *Frontiers in cell and developmental biology*, 13, 1691574.

Flörkemeier I, et al. (2025) Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma. *International journal of molecular sciences*, 26(7).

Habbani SF, et al. (2025) Protein Biomarkers Enable Sensitive and Specific Cervical Intraepithelial Neoplasia (CIN) II/III+ Detection: One Step Closer to Universal Cervical Cancer Screening. *Cancers*, 17(11).

Teng X, et al. (2025) Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening. *EJNMMI research*, 15(1), 22.

Chang X, et al. (2025) Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor-Associated Neutrophils to Sensitize Immunotherapy. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e15511.

Baum R, et al. (2025) A truncated isoform of Connexin43 caps actin to organize forward delivery of full-length Connexin43. *The Journal of cell biology*, 224(3).